Ohlsson Rikard, Geertsen Louise, Berge Stuveseth Stine, Lund Lars
a Department of Urology , Odense University Hospital , Odense , Denmark.
b Department of Clinical Research, University of Southern , Odense , Denmark.
Scand J Urol. 2019 Feb;53(1):9-13. doi: 10.1080/21681805.2019.1585473. Epub 2019 Apr 2.
Cutaneous metastases of renal cell carcinoma (C.M.R.C.C.) are rare and associated with a poor prognosis. The aim of this study is to evaluate the incidence and the prognosis of C.M.R.C.C. with a relevant case report. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (P.R.I.S.M.A.) of existing literature in English and Scandinavian languages was used in the period 1902-2017 with a literature search in PubMed, Embase, and Cochrane Library. Nine original articles were found where the incidence of a C.M.R.C.C. was 3.3% (168/5017). In order to estimate the prognosis of C.M.R.C.C., 161 articles were found with a total of 334 cases. Survival was described in 40% of all cases (132/334). In 31% (102/334) of the cases the final time of death was stated and in this group the mean survival was 10.9 months. Ninety-six per cent died within 36 months after being diagnosed with C.M.R.C.C. C.M.R.C.C. are rare with an incidence of 3.3%. The prognosis is poor with a high mortality. It is suggested that the skin should be examined in the diagnostic evaluation and follow-up for patients with renal cell carcinoma.
肾细胞癌皮肤转移（C.M.R.C.C.）较为罕见，且预后较差。本研究旨在通过一份相关病例报告评估C.M.R.C.C.的发病率及预后。在1902年至2017年期间，采用英文和斯堪的纳维亚语的系统评价和Meta分析的首选报告项目（P.R.I.S.M.A.），在PubMed、Embase和Cochrane图书馆进行文献检索。共找到9篇原始文章，其中C.M.R.C.C.的发病率为3.3%（168/5017）。为评估C.M.R.C.C.的预后，找到161篇文章，共334例病例。40%（132/334）的病例描述了生存情况。31%（102/334）的病例给出了最终死亡时间，该组的平均生存期为10.9个月。96%的患者在被诊断为C.M.R.C.C.后36个月内死亡。C.M.R.C.C.罕见，发病率为3.3%。预后较差，死亡率高。建议在肾细胞癌患者的诊断评估和随访中检查皮肤。
